Which Is the Best Tyrosine Kinase Inhibitor for Newly Diagnosed Chronic Myelogenous Leukemia?

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Frontline therapy choice significantly impacts long-term outcomes for chronic phase chronic myeloid leukemia (CP-CML).
• Five tyrosine kinase inhibitors (TKIs) are available, but no single agent is universally optimal.
• Key factors influencing TKI selection include the EUTOS long-term survival (ELTS) risk score, patient comorbidities, and the priority for achieving treatment-free remission (TFR).

Purpose of the Study:

• To review the determinants of frontline TKI selection in CP-CML.
• To compare the efficacy, tolerability, and safety profiles of available TKIs, including asciminib.
• To discuss considerations for TKI use in pediatric CP-CML and the implications of emergent mutations.

Main Methods:

• Review of current clinical guidelines and trial data for frontline TKI therapy in CP-CML.
• Analysis of factors influencing TKI choice: ELTS score, comorbidities, and TFR.
• Comparison of outcomes from trials evaluating imatinib, second-generation TKIs, and asciminib.

Main Results:

• Higher ELTS scores and lower comorbidity burdens may favor more potent TKIs over imatinib, though no TKI has demonstrated improved survival compared to imatinib.
• In children, imatinib, dasatinib, and nilotinib show similar efficacy; administration ease and toxicity impact quality of life.
• The ASC4FIRST trial indicates asciminib offers superior tolerability and molecular response compared to imatinib and second-generation TKIs, but with a potentially higher rate of emergent BCR::ABL1 mutations, particularly in patients with ASXL1 mutations.

Conclusions:

• Frontline TKI selection in CP-CML requires a personalized approach balancing efficacy, tolerability, and patient-specific factors.
• Asciminib shows promise but requires further investigation regarding mutation emergence, especially in high-risk patients.
• Ongoing research is crucial to optimize TKI strategies and understand long-term implications, including TFR and resistance mechanisms.